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Abstract
Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life-shortening condition. There
have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains
variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging
modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly
encountered clinical and radiological scenarios, and imaging and modeling-based biomarkers. An expert panel was formed including
clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements
based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55
statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in
the diagnosis and assessment of PH and highlight areas requiring further research.
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Introduction
Pulmonary hypertension (PH) is highly heterogeneous, is
challenging to diagnose and treat, and has a survival
worse than many forms of common cancer.1,2 It ranges
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from a rare form, pulmonary arterial hypertension (PAH),
characterized by a vasculopathy and frequently severe elevation of pressure, to more common usually mild elevations
of pulmonary artery pressure (PAP) seen in severe cardiac
and respiratory disease.3,4 The current system of classiﬁcation identiﬁes ﬁve groups, each with distinct pathophysiological characteristics.2,3,5 The diagnosis of PH is usually
ﬁrst suggested by echocardiography or chest radiography
with conﬁrmation of an elevated PAP at right heart catheterization (RHC). Phenotyping is based on a careful history, blood testing for associated conditions, detailed
physiological, and imaging investigations.
The treatment of PH is dependent on the underlying cause.
For patients with PAH, drug therapy targeting imbalances in
vasoconstrictor and vasodilator mediators have been shown
to improve exercise capacity, quality of life, and event-free
survival.6–13 However, PAH remains a life-limiting and debilitating condition. In chronic thromboembolic pulmonary
hypertension (CTEPH), pulmonary endarterectomy is an
established technique with excellent long-term outcomes14–18
and, more recently, drug therapy19–21 and balloon pulmonary
angioplasty (BPA)22,23 have shown beneﬁt in selected groups
of patients with CTEPH. For patients with other forms of
PH, such as in association with cardiac and respiratory disease, trials of PAH therapies have thus far been disappointing.24–26 Accurate classiﬁcation is key, not only as it deﬁnes
treatment but also prognosis27–29 and careful assessment
is therefore crucial in the assessment of patients with suspected PH.
Current assessment tools in the PH clinic and endpoints
used in clinical trials may be limited by a number of factors.
These include insensitivity to change, lack of repeatability,
and the invasive nature of tests. There is a need to identify
new tools and endpoints to aid the physician both in the
clinical environment and in studies of new interventions.30–36 Importantly, over the last 20 years, there has
been major advances in imaging techniques and their application including the use of echocardiography, nuclear medicine, computed tomography (CT) scanning, magnetic
resonance imaging (MRI), and molecular imaging.
There is growing evidence demonstrating the value of various imaging modalities in the classiﬁcation, risk stratiﬁcation, and follow-up of patients with PH. Imaging studies
have also provided insights into pathophysiological
mechanisms.37–45
The use of imaging varies across the globe due to a variety of factors including personal preference, availability,
and cost. Given the complex nature of certain imaging investigations, there are also diﬀerences in methods of scan acquisition and post-processing within a given modality.
Consequently, the Pulmonary Vascular Research Institute
(PVRI) have identiﬁed imaging as an important area for
international collaboration, with the aim of developing evidence-based statements and sharing best practice, while
recognizing that approaches need to be tailored to imaging
availability. This statement on imaging in PH is aimed at

physicians (including cardiologists and pulmonologists), PH
specialists, radiologists, and imaging scientists.

Methods
The PVRI Imaging Task force met for the ﬁrst time in Rome
in 2016 with an aim of improving imaging practice globally
in PH. A summary statement from the PVRI was identiﬁed
as an important ﬁrst step in achieving this goal. Participants
were invited from the existing PVRI membership in addition
to international imaging experts. The group included representatives from wide-ranging professional backgrounds and
diﬀerent geographical areas with varied access to imaging.
Groups of authors were assigned to speciﬁc sections to
review current literature, identify summary statements, and
develop a diagnostic algorithm. An editorial board met to
preview and reﬁne summary statements and ensure uniformity of style (DGK, DL, JVC, and AJS). To be included in
the ﬁnal document, summary statements required agreement
of 80% of authors. Statements not meeting this requirement
were reworded until this threshold was reached or the statement rejected. Given the rapid development of imaging technologies, the recommendations reﬂect a combination of
published evidence, current practice, and expert opinion.
All authors read and approved the manuscript before
submission.

Section 1: Imaging modalities used in the
assessment of PH
1.1 Chest radiography
Summary statements
1. A chest radiograph is recommended as the initial imaging
test in the assessment of unexplained breathlessness.
2. A normal chest radiograph does not exclude the diagnosis of PH
3. Features of PH include pulmonary artery (PA) enlargement and cardiomegaly.

Chest radiography. Patients with PH frequently present with
breathlessness. The principal role of the chest radiograph
(CXR) is to identify other common causes of breathlessness
(e.g. parenchymal lung disease, pneumonia, pulmonary
edema, pleural eﬀusion, and pneumothorax). The ﬁndings
of PH on CXR vary. There may be enlargement of the central pulmonary arteries with pruning of the peripheral vessels, features that were observed in the majority of patients
in a registry of patients with idiopathic PAH.46 In addition,
cardiomegaly and features suggestive of right atrial enlargement may be observed. However, a normal CXR cannot
exclude the diagnosis and the CXR may be normal, where
PAP elevation is modest. Radiographic features may also
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suggest the cause of PH, such as upper lobe venous diversion and left atrial enlargement in patients with left heart
disease, vascular plethora, and peripheral pruning in
patients with Eisenmenger physiology, and interstitial opacities in patients with diﬀuse parenchymal lung disease.

1.2: Echocardiography
Summary statements
1. Echocardiography is the test of choice in the initial evaluation of suspected PH.
2. Echocardiography should include an assessment of PAP,
cardiac, and valvular function.
3. A probability of PH should be generated using estimated
PAP and additional echocardiographic features.
Doppler and two-dimensional (2D) echocardiography
remains the screening test of choice in the evaluation of suspected PH.47–50 While right ventricular systolic pressure
(RVSP) from the continuous wave Doppler of the peak tricuspid regurgitant velocity (TRV) is the most well-known
tool for assessing the presence or absence of PH, this metric
can be subject to several limitations resulting in over or under
estimation of the true pulmonary artery systolic pressure
(PASP).51 Over the last decade, there have been many studies
evaluating the role of clinically useful and readily available
echo-Doppler parameters that allow one to move beyond the
PASP and assess not just the likelihood of PH, but also the
hemodynamic underpinnings of the disease (i.e. left heart disease vs. PAH).52,53 As noted in the most recent European
Society of Cardiology (ESC)/European Respiratory Society
(ERS) PH guidelines, ‘‘echocardiography should always be
performed when pulmonary hypertension is suspected and
may be used to infer a diagnosis of pulmonary hypertension
in patients in whom multiple diﬀerent echocardiographic
measurements are consistent with this diagnosis,’’ even in
the absence of an elevated TRV.54 This can then be used to
generate a probability of PH which will inform the diagnostic
strategy and ‘‘decide the need for cardiac catheterization in
individual patients.’’54 Furthermore, several echo-Doppler
parameters have been shown to have prognostic value in
the setting of established PH.
Clinically useful measures of PH (i.e. elevated RV afterload) on echocardiography include characteristics of the RV
outﬂow tract (RVOT) pulse wave Doppler envelope such as
a reduced acceleration time (<100 ms),53,55–57 systolic notching,53,58,59 and pulmonary insuﬃciency velocity to estimate
mean PAPs (mPAP), as well as interventricular septal ﬂattening (as characterized by the eccentricity index),60
increased right-to-left ventricular ratio (0.8–1.0, 1.1–1.4,
and 1.5 corresponding to mild, moderate, and severe RV
dilatation, respectively),52,54 RV hypertrophy and right
atrial dilation61 and measures of RV function including tricuspid annular plane systolic excursion (TAPSE),62,63 and
RV fractional area change (RVFAC).63–65 While RVFAC is
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often limited in the setting of severe RV enlargement,52,63,66
TAPSE is a reproducible measure of RV function which
measures the total displacement of the heart from the RV
base toward the apex in systole, and correlates with radionuclide-derived RV ejection fraction (RVEF).63 TAPSE has
also been shown to be prognostic of poor outcome in PH in
all-comers,62 as well as in follow-up assessment in a PAH
population after initiation of PH therapy.67,68 However,
TAPSE has not been shown as an eﬀective marker of RV
function in pediatric PH.69 Other echocardiographic measures include the myocardial performance (Tei) index70 and
S’ obtained from tissue Doppler imaging of the tricuspid
annulus.71 Markers of adverse outcomes include pericardial
eﬀusion and enlarged right atrium.72 More recently, RV
longitudinal strain using 2D speckle tracking has been
employed in the quantiﬁcation of RV function in patients
with PH and has been shown to be impaired in patients with
PH, a predictor of mortality73–76 and useful for assessment
of therapy response.77,78 Lastly, given the complex anatomy
of the right ventricle, recent investigation has focused on the
use of three-dimensional (3D) echocardiography79 and
strain to assess global and regional RV structure and function and predict outcomes in PH.80

1.3 Nuclear medicine imaging
Summary statements
1. A normal perfusion single photon emission computed
tomography (SPECT) excludes chronic thromboembolic
disease that will beneﬁt from pulmonary endarterectomy
and BPA.
2. Ventilation and perfusion SPECT or SPECT CT is superior to planar scintigraphy.
3. In unexplained hypoxemia, a nuclear medicine shunt
assessment can be used to identify the presence of a
right-to-left shunt.
4. In patients with suspected PA sarcoma, positron-emission tomography (PET) is recommended.
Ventilation/perfusion (V/Q) SPECT is recommended by the
ESC as the ﬁrst line screening test for patients with
CTEPH.1 The technique is well established and has excellent
diagnostic value particularly in the absence of lung disease.
The perfusion image involves exposure to ionizing radiation
and requires injection of 99mTc labelled macroaggregated
human albumin (10–90 mm in diameter).20 The macro-aggregated albumin becomes trapped within the small pulmonary
arterioles and a 3D image of pulmonary perfusion is acquired.
In CTEPH, typically peripheral wedge-shaped defects of varying size are shown. Mismatch to ventilation can be conﬁrmed
by comparing ventilation and perfusion images. The added
value of performing ventilation imaging is debated and in
many centers perfusion imaging alone is performed and compared to CT which better demonstrates parenchymal lung disease. CTEPH may be missed on CT as attenuated distal
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vessels, subsegmental stenosis, and webs may not be appreciated. Early studies demonstrated that scintigraphy was
more sensitive than CT for the detection of CTEPH.
However, given advances in technology, more recent studies
have shown that CT pulmonary angiography and CT SPECT
techniques are equally sensitive.21–23 Dual-energy CT (DECT)
or CT with iodine mapping allow construction of relative perfusion maps in addition to providing angiographic images.81–87
Given that 99mTc labelled macroaggregates are trapped by
small pulmonary arterioles, the presence of radioactive
uptake in organs supplied by the systemic circulation (e.g.
the kidneys) can be used to identify the presence of a rightto-left shunt in hypoxemic patients with PH.19
Positron-emission tomography (PET) allows for observation of metabolic activity in the body which can be reconstructed to produce 3D images. Fluorodeoxyglucose (FDG),
a glucose analogue, can be used to assess glucose uptake in
tissues. PET scanning is commonly performed with simultaneous acquisition of CT and more recently with MRI for
both functional and structural correlation.28 In patients with
suspected PA sarcoma, PET will show high uptake allowing
diﬀerentiation from chronic clot.29,30 However, in acute clot
FDG, uptake may also be elevated, relative to unaﬀected
vessels.88 In PAH, uptake within the lungs and right ventricle have been demonstrated24–27 although the clinical utility is uncertain.

1.4 Computed tomography
Summary statements
1. CT provides a non-invasive evaluation of vascular, cardiac, lung parenchymal, and mediastinal structures in
patients with known or suspected PH.
2. Signiﬁcant parenchymal abnormalities may be seen on
CT evaluation in the presence of normal spirometry, particularly when there is a signiﬁcant reduction in gas transfer factor.
3. CT pulmonary angiography to assess the pulmonary
vasculature should be considered in patients presenting
with PH.
4. Imaging biomarkers from CT in patients with suspected
PH should include measurement of PA size, right-to-left
ventricular ratio, and left atrial size.
5. CT aids the classiﬁcation of PH.
CT is increasingly recognized as a valuable imaging modality for the evaluation of known or suspected PH.
Advantages of CT include its widespread availability and
accessibility, high spatial resolution, multi-planar imaging
capabilities, and the ability to evaluate the pulmonary vasculature, lung parenchyma, cardiac, and mediastinal structures simultaneously.
CT evaluation of vessels. PA size can be easily measured and
enlargement may suggest the diagnosis of PH. Routine

measurement is recommended particularly in patients at
risk of PH. For the diagnosis of PH in lung disease, a
main PA diameter >29 mm had 84% sensitivity, 75% speciﬁcity, and 97% positive predictive value (PPV) for PH
deﬁned as a mPAP  25 mmHg.89 The reliability of measuring the main PA diameter and the ratio of the PA to aorta
(Ao) ratio has also been studied in suspected PH.
Investigators found that a PA:Ao ratio > 1 was 92% speciﬁc
for a mPAP > 20 mmHg.90 Other reports also support the
use of PA size in the clinical assessment of patients with
PH.91,92 However, it has been shown that an increase in
PA size also reﬂects disease duration and correlates only
moderately with PAP.93 It has previously been postulated
that the presence of interstitial lung disease independently
inﬂuences PA size;94 however, in a large cohort of patients
with suspected PH in association with interstitial lung disease, the presence and severity of interstitial lung disease did
not inﬂuence PA size which was found to be a useful diagnostic marker in patients with and without interstitial lung
disease.95
While contrast-enhanced CT angiography is the method
of choice for the evaluation of suspected acute pulmonary
embolism, its role in the evaluation of the pulmonary vasculature in the setting of CTEPH has been a more recent
development. Multiple ﬁndings are associated with CTEPH,
including intravascular organizing thrombi, webs, and
regions of vascular narrowing or occlusion.96 Mosaic perfusion of the lung parenchyma and enlarged bronchial arteries
are also commonly seen.97–99
Advanced CT capabilities have been studied in the evaluation of PH. DECT provides an assessment of relative perfusion and improves the detection of peripheral vascular
occlusion. In one study,85 DECT showed 100% sensitivity
on a per-patient basis compared to V/Q scintigraphy.
However, there was imperfect agreement on a per-vessel
basis. CT perfusion imaging may demonstrate residual perfusion abnormalities following therapy for acute pulmonary
embolism, even in the absence of visualized thrombus on the
angiographic portions of the study.100 Perfusion imaging
can also estimate cardiac output and in a small pilot study
could detect PH with high sensitivity and speciﬁcity.101,102
PAH is associated with vascular remodeling, including
loss of arterial branching and increased vessel tortuosity.
CT angiography can quantify these features, using fractal
dimension and the ratio of actual vessel length to shortest
linear distance to estimate tortuosity. Studies have shown
these to correlate with hemodynamic measures in PAH.103
However, changes in the fractal dimension were found only
in children with PAH, but not in adults.104 Loss of distal
vascular volume has also been described in patients with
severe emphysema105 and in patients with CTEPH.106
CT evaluation of lung parenchyma. CT is the gold standard for
the evaluation of the lung parenchyma. In a large registry
series, CT measures have proven useful clinically in
the assessment of patients with PAH.38 Centrilobular
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ground-glass opacities are frequently seen in PAH and their
presence on a CT performed for unexplained breathlessness
should raise the possibility of this diagnosis.38,107,108
Features of cardiac decompensation, pleural eﬀusion/
septal lines, and inferior vena cava size predict outcome.38
The presence of emphysema or interstitial lung disease or
bronchiectasis makes the diagnosis of PH in association
with lung disease likely. The addition of expiratory imaging
is helpful to assess for small airways disease. CT may also
identify features associated with rare conditions such as pulmonary veno-occlusive disease (PVOD) and pulmonary
capillary hemangiomatosis (PCH) (section 2.2). This is an
important diﬀerential diagnosis to idiopathic PAH (IPAH)
because PAH therapy may be indicated but has a much
higher risk of severe adverse eﬀects than IPAH.
CT evaluation of cardiac structure and function. CT has historically not been used for the evaluation of cardiac structural
abnormalities as MRI and echocardiography are the current
modalities of choice. Nonetheless, many cardiac ﬁndings
associated with PH can be identiﬁed with non-gated contrast-enhanced CT, including enlargement of cardiac chambers, thickening of the RV free wall, and leftward deviation
of the interventricular septum. CT can also identify structural abnormalities associated with congenital heart disease,
such as partial anomalous pulmonary venous return and
intracardiac shunts. Electrocardiogram-gated CT can be
used to quantitatively assess RV and left ventricular (LV)
function. Additionally, a decrease in distensibility of the
main PA is highly correlated with the presence of
PAH.109–111 A study has shown that dynamic contrastenhanced CT can measure the transit of contrast, correlated
with cardiac output.102 and is associated with the presence
of PH.101
CT evaluation of mediastinal structures. CT provides detailed
imaging within the mediastinum and may demonstrate ﬁndings that give information as to the etiology or severity of
PH. Dilatation of bronchial arteries is a common ﬁnding in
CTEPH, but less common in other forms of PH.97,112 A
dilated esophagus in the setting of PH suggests the diagnosis
of systemic sclerosis. Other mediastinal ﬁndings, while not
speciﬁc to a given etiology, may suggest a poor prognosis.
These include the presence of pericardial eﬀusion, lymphadenopathy, and reﬂux of contrast into the hepatic veins.38

1.5 Magnetic resonance imaging
Summary statements
1. MRI enables comprehensive cardiac evaluation in
patients with suspected PH.
2. MRI is the gold standard technique for the assessment of
biventricular morphology and function and is highly suitable for monitoring patients with PH.
3. MRI provides prognostic value in PAH.
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4. MRI aids the classiﬁcation of PH particularly for left
heart disease and chronic thromboembolic disease.
Cardiac MRI is the gold standard for quantiﬁcation of RV
volumes, mass, function, and ﬂow hemodynamics in the pulmonary circulation.113,114 Cardiac MRI techniques allow for
non-invasive assessment of RV function and structure using
high spatiotemporal resolution imaging sequences with high
accuracy and reproducibility without exposure to radiation.113 Furthermore, cardiac MRI can be used for assessment of myocardial tissue deformation properties (strain),
global structural evaluation, and perfusion.115–117
Right ventricular size and function. RV hypertrophy and dilation reﬂect an increased afterload.5 In particular, in
advanced stages of PH, a severely dilated and functionally
compromised right ventricle has a negative eﬀect on LV
diastolic function by means of leftward septal shift and
reduced LV ﬁlling associated with decreased RV stroke
volume. Indeed, both RV and LV dimensional metrics
have been shown to have diagnostic potential in treatment-naı̈ve patients with PH and prognostic value in both
adult and child populations.118–120 MRI-derived bi-ventricular functional and volumetric indices have been shown to
have independent prognostic potential and diﬀerentiated
incidental treatment-naı̈ve and prevalent patients in a large
group of patients (n ¼ 576).121 Cine MRI derived indices
including interventricular septal bowing, LV eccentricity,
and ventricular dyssynchrony due to prolonged RV contraction time have been shown to correlate with invasive hemodynamics and are reﬂective of the overall hemodynamic
condition and disease severity.122,123 Septal deviation measured by MRI is useful for the diagnosis of PH, but also in
patients with left heart disease septal deviation > 160 can
identify patients with elevated diastolic pulmonary gradient.124 In addition, MRI has proven useful in the diagnosis
of PH in patients with chronic obstructive pulmonary
disease (COPD), typically a challenging cohort for
echocardiography.125
Late gadolinium enhancement and T1 mapping. Late gadolinium
enhancement (LGE) imaging is used to identify focal myocardial pathology but has also been applied to investigate
regional myocardial disease in the right ventricle as a
response to elevated mechanical stress. The predominant
focus has been on the RV free wall insertion sites to
septum and how the extent of LGE corresponds to RV morphological and dynamic changes.44,45,126–130 Speciﬁcally,
LGE was correlated with the reduced RV function, dilation,
mass, and regionally speciﬁc LGE was also inversely associated with reduced longitudinal strain.128,131 Additionally,
the presence of delayed enhancement at the RV insertion
points has been associated with clinical worsening,127
though in a study using mortality as the endpoint, RV insertion point LGE was not of independent prognostic signiﬁcance. Extension of the LGE into the interventricular
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septum was of prognostic signiﬁcance at univariate analysis but was not signiﬁcant at multivariate analysis.45 A
limited number of studies have explored the role of coronary
arterial ﬂow in PH.117,132 Features may be seen in patients
with PH with LGE imaging; however, its utility in the routine assessment of suspected PH is not proven. LGE imaging
can be considered where intrinsic cardiac disease is
suspected.
T1 mapping is a quantitative method of assessing myocardial health. Native T1 mapping is performed without the
use of contrast agents and has been shown to be an excellent
diﬀerentiator between a healthy and diseased myocardium.133 T1 has been shown to be elevated at the insertion
points in PH in animal134 and human studies.135–137 T1 correlates with markers of RV remodeling135 and septal position;138 however, no clear diagnostic or prognostic role has
been identiﬁed in PH.138
Right ventricular strain. Myocardial tissue deformation analysis has been assessed in patients with PH.139–141 RV
morphology limits myocardial tagging and feature tracking
to global longitudinal and circumferential deformation analysis. MRI-based feature tracking has been shown to have
prognostic potential and was associated with the severity of
PH.142 Measuring LV strain and torsion using tag MRI as
part of ventricular interdependency and dyssynchrony investigations in CTEPH revealed left–right ventricular resynchronization post endarterectomy.143 However, the clinical
utility of deformation analysis is yet to be determined.
Pulmonary artery and aortic flow measurements. Phase-contrast
MRI (PC-MRI) enables assessment of ﬂow waveform in
major vessels and allows for accurate Qp:Qs assessment,
necessary in patients with suspected congenital lesions.114
Phase-contrast MRI of pulmonary ﬂow is recommended
for assessment of RV stroke volume due to variable tricuspid regurgitation and the challenges of contouring the right
ventricle.144 Relative area change of the PA has been shown
to be of clinical value,145,146 and recently has been shown to
be independent of RV measurements and clinical data.37
Black blood slow ﬂow has been shown to be a strong diagnostic marker as the ﬂow characteristics of the main and
branch vessels are visualized.147,148 Four-dimensional ﬂow
MRI (4D-Flow MRI) is an emerging technique allowing
evaluation of ﬂow, vorticity, and kinetic energy in any
region of interest. Vortices have been noted in the main
PA of patients with PH. The lifetime of the existence of a
vortex has been shown to correlate with mPAP and may
have utility in the identiﬁcation of PH.149–152 4D ﬂow also
has the additional beneﬁt that it allows retrospective ﬂow
evaluation by selecting a 2D slice in any plane of the 4D
dataset,153 whereas current techniques rely on the slice positioning at the time of the scan.
3D MR perfusion and angiography. MR angiography (MRA)
can show characteristic vessel patterns in subtypes of PH,

including pruning in IPAH, thromboembolic obstruction
and stenosis in CTEPH, and splayed vessels in COPD/
emphysema.113 MRA is useful for the assessment of chronic
embolus in the lobar and segmental PA vessels. Beyond the
segmental level, assessment of the PAs with MRA is very
challenging.96 In addition, a central embolus, particularly a
wall adherent clot, can be missed if MRA is reviewed in
isolation; standard white blood MRI sequences can assist
with visualization of a central clot.96
Dynamic contrast-enhanced MRI perfusion is a promising technique for the assessment of chronic thromboembolic
disease allowing visualization of pulmonary perfusion
defects with sensitivity and speciﬁcity similar to that
achieved with SPECT,39 with the advantages of higher spatial resolution and lack of ionizing radiation. Time-resolved
MRA or dynamic contrast-enhanced (DCE) imaging can be
used to measure passage of contrast bolus through the heart
and lungs to assess pulmonary perfusion.154,155 This can be
used to measure mean transit time, time to peak, and blood
volume.152,156,157

1.6 Imaging in conjunction with invasive techniques
Summary statements
1. Catheter-based angiography is used primarily to assess
patients with CTEPH considered as potential candidates
for pulmonary endarterectomy or BPA.
2. Performance of catheter-based angiography requires
skilled operators and should generally be performed in
a PH referral center.
3. Non-invasive imaging approaches can be used to select
patients for pulmonary endarterectomy.
4. Imaging measurements combined with catheter measurements may be used to study RV pressure and volume
relationships.

Digital subtraction angiography. Catheter-based angiography
involves rapid imaging of the PAs during the injection of
contrast material through a catheter placed into the pulmonary arterial system.158,159 This used to be the primary
method for evaluation of the pulmonary vasculature.
However, given the development of CT and MR methods,
these modalities can also be used.96,106,160 Catheter-based
angiography may be used at expert institutions for the
evaluation of chronic thromboembolism before pulmonary
endarterectomy and is required for BPA.
Assessment of ventricular-arterial coupling. Imaging can be incorporated with invasive catheter-based methods for characterization of the mechanics of the right ventricle and the
pulmonary arteries. Flow and volumetric MRI measurements in conjunction with pressures obtained from RHC
can be used for assessment of ventricular-arterial coupling.161–163 One method for determining RV contractility
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involves computation of the pressure-volume loop while
using balloon occlusion of the inferior vena cava, permitting
a preload independent assessment of ventricular contractility.164 In practice, this method requires use of conductance
catheters or the measurement of pressure and ﬂow at the
same time in order to construct the pressure volume loops
with diﬀerent degrees of preload modulated by the occlusion
of the inferior vena cava. Conductance catheters typically
require calibration of the volume signal from imaging, typically a baseline cardiac MRI. The ‘‘Single Beat’’ method
using a cardiac catheter can be used to estimate Pmax. This
has been used in conjunction with MRI to measure ventricular volumes and can serve as a surrogate for Ees/Ea,165 the
relative utility of information from these methods remains
an area of research.166 Cardiac MRI has been used to measure stroke volume and RV volumes and in conjunction with
pressure measurements to construct pressure-volume loops
and estimate RV contractility.167–170 An entirely MRI-based
non-invasive method of measuring RV to PA coupling has
been proposed, deﬁned by RV stroke volume/RV end-systolic volume; however, this holds similar information to
RVEF (right ventricular stroke volume / right ventricular
end-diastolic volume).171 Studies have suggested added
prognostic value of coupling measurements,172,173 although
a recent large study suggested it did not add additional prognostic signiﬁcance over RV volume alone in patients with
PAH.121

Section 2: Imaging adults with pulmonary
hypertension
2.1 The accuracy of cross-sectional imaging to diagnose
pulmonary hypertension and assess pulmonary
hemodynamics
Summary statements
1. A number of CT and MRI ﬁndings are characteristic of
PH.
2. Current qualitative approaches to imaging cannot be
used to conﬁdently exclude the presence of PH.
3. Quantitative data obtained from imaging can be used to
diagnose PH and estimate pulmonary hemodynamics.
CT imaging is widely available and measurement of the
PA size has been shown to correlate with mPAP;174 however, in established PH, there are progressive increases in PA
size over time.175 Pulmonary artery enlargement may
be seen in interstitial lung disease in the absence of PH,94
although a recent publication has shown equivalent diagnostic accuracy in patients with and without interstitial
lung disease. In patients with systemic sclerosis in the
absence of interstitial lung disease, a ratio of main PA
to Ao diameter of at least 1 was highly predictive of
the presence of PAH although a normal ratio did not
exclude PAH.176
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MRI is non-invasive, reproducible, and is considered the
gold standard for assessing RV function.177 Studies have
shown a high correlation between RV mass and ventricular
mass index (VMI), the ratio of right-to-left ventricular mass,
and mPAP pressure measured at cardiac catheterization.178,179 Recently investigators have shown that combining VMI and septal curvature improves the accuracy of
estimating mPAP.180 By using MRI to calculate left atrial
volume, pulmonary arterial wedge pressure (PAWP) can be
estimated allowing calculation of the trans-pulmonary gradient.180 Cardiac output can be calculated from LV volumetric measurements or phase contrast of ﬂow in the PA or
Ao allowing an entirely non-invasive estimate of pulmonary
vascular resistance (PVR) based on individually derived
MRI measurements. Models using RVEF and average PA
velocity have also demonstrated accuracy for estimating
catheter-derived PVR.181 Studies comparing cardiac magnetic resonance cardiac MRI and RHC in patients suspected
of PH have shown that an elevated VMI, reduced PA velocity, and the presence of increased gadolinium at the hinge
points could predict the presence of PH with a positive predictive value of >0.9 although no cardiac MRI measure
could conﬁdently exclude PH.179 In summary, although
able to estimate pulmonary hemodynamics and identify
PH with high accuracy in certain groups, imaging is currently unable to exclude PH.

2.2 How helpful is imaging in identifying the cause of
pulmonary hypertension and subtyping?
Summary statements
1. Diﬀerent forms of PH and their subtypes may exhibit
characteristic imaging features.
2. Echocardiography and MRI are useful for diﬀerentiation
of pre and post capillary PH.
3. CT provides an accurate evaluation of lung structural
abnormalities.
4. Nuclear medicine, CT and MR perfusion imaging can be
used to exclude chronic thromboembolic disease.
5. Diﬀerent combinations of imaging modalities can be
employed tailored to local expertise and availability.
Many of the imaging ﬁndings associated with PH are
common to most or all disease processes leading to PH.
These ﬁndings may include enlargement of the central
PAs, right-sided cardiac enlargement, and abnormalities of
lung attenuation. Some imaging ﬁndings, however, are more
speciﬁc and can help to distinguish among the various
causes of PH. These are discussed in the following section.
Pulmonary arterial hypertension (group 1). Within group 1 PAH,
imaging ﬁndings may suggest a speciﬁc etiology. Patients
with systemic sclerosis typically have a dilated esophagus,
a central ground glass pattern, and often associated interstitial lung disease. Drug and toxin exposures may also be
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associated with mild parenchymal ﬁbrosis or mosaic lung
attenuation. In patients with portopulmonary hypertension,
the presence of varices, features of liver cirrhosis, and
splenomegaly are frequent. Anomalous pulmonary venous
drainage should be sought as this is frequently associated
with congenital heart disease, in particular a sinus venosus
atrial septal defect which is diﬃcult to detect by transthoracic echocardiography. An interatrial shunt may also be
suggested by contrast visualized entering the left atrium
via the interatrial septum. While enlargement of the PAs is
common to all forms of PAH, it is greatest in patients with
Eisenmenger physiology.38 Patients with Eisenmenger physiology may also have laminated proximal thrombus and calciﬁcation within the wall of the PA. Bronchial artery
enlargement is most frequently observed in CTEPH but is
also observed in patients with congenital heart disease182
and patients with IPAH and a BMPR-2 mutation.183
PVOD is rare and is characterized by mediastinal lymphadenopathy and interlobular septal thickening,184,185 with or
without associated ﬁndings of alveolar edema, mediastinal
lymphadenopathy in the setting of a normal sized left
atrium. PCH is frequently associated with nodular foci of
parenchymal inﬁltration. The triad of peripheral interlobular septal thickening, centrilobular ground-glass opacities,
and mediastinal lymphadenopathy has a good association
with PVOD and PCH.184,186,187

Pulmonary hypertension due to left heart disease (group 2), pulmonary hypertension due to lung diseases (group 3), and pulmonary
hypertension with unclear and/or multifactorial mechanisms (group
5). Within these groups, imaging may be useful to identify
either left-sided cardiac enlargement (group 2) or diﬀuse
lung disease (groups 3 or 5). Many lung diseases will have
a distinctive radiographic appearance allowing for speciﬁc
diagnosis and grading of severity. Characteristic structural
features of patients with left heart disease which can be
visualized on both CT and MRI include left atrial enlargement,188–190 absence of posterior displacement of the interventricular septum,179 and relatively normal RV volumes,
although RV enlargement is seen in more severe disease particularly in the setting of severe tricuspid regurgitation. The
presence of valvular and coronary artery calciﬁcation and
evidence of previous cardiac surgery are more common in
left heart disease although may also be present in patients
with other forms of PH. Echocardiography and MRI allow
a comprehensive functional assessment. Patients with left
heart disease have less RV hypertrophy and compared to
pre-capillary forms of PH have better preserved RV function. The absence of paradoxical septal motion/septal displacement in the setting of high right-sided pressures infers
an increase in left-sided pressures. Echocardiography allows
assessment of both systolic and diastolic dysfunction and
the identiﬁcation of valvular heart disease, in addition to
identifying features suggestive of combined post- and precapillary disease.191

Chronic thromboembolic pulmonary hypertension (CTEPH) and other
pulmonary artery obstruction (group 4). A large prospective
study estimated the risk of developing CTEPH after a pulmonary embolism at 3.8% at two years.192 Imaging plays a
critical role in the evaluation of suspected CTEPH, although
the exact role of each imaging modality is debated. Some of
this uncertainty reﬂects the rapid development of imaging
technologies. Chest radiographs may suggest the diagnosis
of CTEPH – with cardiomegaly, asymmetrical pulmonary
artery enlargement, pruning of the vasculature and subpleural scarring; however, they are not diagnostic.
Historically decisions on diagnosis and surgical management were based on V/Q scintigraphy and conventional
pulmonary angiography with RHC. The role of V/Q scintigraphy (either planar or SPECT imaging) has changed.
SPECT is recommended over planar imaging as it has
higher diagnostic accuracy.193
The current ESC/ERS guidelines recommend that V/Q
scintigraphy be performed in all patients with suspected
CTEPH.194 These recommendations for V/Q scanning are
in part based on clinical experience, previous recommendations, and on older data.195–197 These data demonstrated a
signiﬁcant improvement in the detection of CTEPH with
scintigraphy compared to CTPA. However, rapid developments in CT technology have led to marked improvement in
disease detection and characterization. More recent studies
in experienced centers demonstrate that CTPA has high
diagnostic accuracy for CTEPH.39 Key imaging ﬁndings
include identiﬁcation of eccentric thrombus, intravascular
webs, stenoses with or without post-stenotic dilatation,
and occlusions. Bronchial artery dilatation (commonly
described as a diameter of >2 mm) is more commonly seen
than in other forms of PH. The presence of bronchial artery
dilatation is associated with a better outcome following pulmonary endarterectomy. A mosaic perfusion pattern is seen
in the vast majority of patients with CTEPH. Its presence
should alert the observer to the possibility of CTEPH but
should be diﬀerentiated from the mosaic pattern seen in
small airways disease where often single or small clusters
of lobules are involved in contrast to larger geographical
areas typically seen in CTEPH. Performance of expiratory
CT may be helpful in this setting. Peripheral areas of subpleural scarring and cavitation representing healed infarcts
may also be seen in approximately 10% of patients with
CTEPH.198 DECT imaging generates maps of regional
iodine density in the lung parenchyma as a surrogate for
perfusion. This may further improve the evaluation of suspected CTEPH by better demonstrating regions of
decreased or absent blood ﬂow199 and has been shown to
have excellent agreement with SPECT.200 Although the
availability of this technology is relatively limited, iodine
mapping using CTPA with an unenhanced pre-scan is an
emerging technique, which generates a lung perfusion
map. In contrast to DECT, it does not require specialized
hardware but involves subtraction of unenhanced images
from the contrast-enhanced study. This has the advantage
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that subtle abnormalities that may be missed on the angiography are unlikely to be overlooked on a perfusion map thus
improving detection of subtle webs and distal disease.81
By providing an assessment of the lung parenchyma and
the mediastinum CT can be helpful in identifying the presence of diﬀuse lung diseases and emphysema (groups 3 and
5) and excluding pulmonary vascular obstruction from a
central mass. Parenchymal evaluation may also be valuable
in identifying features suggestive of interstitial edema,
PVOD, or vasculopathy though there is overlap in the imaging features. CT may also identify features suggestive of
large vessel vasculitis or PA sarcoma which may not be
readily appreciated on projectional angiography.
MRI can also provide an evaluation of the pulmonary
vasculature and is increasingly being used in select centers
for the evaluation of known or suspected CTEPH. 4D DCE
lung perfusion MRI techniques201 are widely available on
current MRI systems and have shown excellent test performance in diagnosing CTEPH in a single center registry
setting.39 In addition, a non-contrast, free-breathing ventilation perfusion MRI technique, known as the Fourier
Decomposition (FD)-MRI method202,203 has recently
shown initial encouraging results in diagnosing chronic pulmonary embolism;204 however, this technique needs to be
conﬁrmed in larger multicenter studies. Combined
cardiac MRI and time-resolved MRA exam is suitable for
detailed treatment response evaluation before and after pulmonary endarterectomy as well as BPA in CTEPH
patients.205,206
CTPA has largely replaced invasive catheter-based angiography as the initial morphological test for PA evaluation
in most centers. However, catheter-based angiography may
still have a role in the evaluation of CTEPH. Older data
suggest that catheter-based angiography may provide a
better assessment of the extent of pulmonary vascular
obstruction than V/Q scintigraphy.207 Additionally, some
expert centers prefer catheter-based angiography for evaluation of the extent of thrombotic disease before PEA.208
Again, CT performance relative to catheter-based angiography is generally poorer in older studies159 compared to
more recent data.209,210 This diﬀerence again likely reﬂects
signiﬁcant advances in CT technique and technology as well
as greater awareness of CTEPH and its imaging features in
imaging circles. When there is diagnostic uncertainty regarding the extent and distribution of chronic thromboembolic
changes on the basis of a single imaging modality
(usually CT), the use of a second morphologic imaging
modality (MRA or catheter-based angiography) may
prove complementary by improving conﬁdence in subtle
lesions or identifying others. This can augment surgical
decision-making.
In recent years, BPA has emerged as an eﬀective therapeutic modality in selected patients with CTEPH. This has
put greater emphasis on the evaluation of distal segmental
and subsegmental vasculature. It is generally considered that
at the subsegmental level, catheter-based angiography
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outperforms non-invasive morphological techniques (CT/
MRI) which has resulted in increased utilization. Clinical
criteria and imaging algorithms for the selection of patients
for BPA vary between centers but catheter-based diagnostic
angiography for potentially suitable candidates permits conﬁrmation of suitable extent and distribution of disease as
well as the patients ability to tolerate a BPA procedure (ability to maintain breath-hold and tolerate the required period
on the catheter table).211

2.3 Echocardiography and cardiac MR: what are the
advantages and disadvantages of each modality?
Summary statements
1. Echocardiography is more widely available, lower in cost,
and more portable than MRI.
2. Echocardiography is superior to MRI for the evaluation
of valvular heart disease and is more established in the
assessment of diastolic function.
3. MRI provides more accurate quantitative assessment of
RV morphology and function.
4. MRI is more suited to serial assessment than echocardiography due to higher reproducibility.
Echocardiography and cardiac MRI provide value in the
assessment of patients with PH. Echocardiography is well
established in the initial assessment of patients with suspected PH. It has also been evaluated in the serial assessment of patients with PH66,67 and has been found to be
prognostic and is recommended in current guidelines at
follow-up and following treatment change.
Technical factors. Echocardiography has high temporal resolution, is widely available, low in cost, portable, and less
aﬀected by arrhythmia than MRI although real-time imaging212 has helped to counter this limitation at the cost of
lower spatial resolution. Echocardiography is more operator-dependent and is less reproducible. MRI has the advantage that it has better contrast resolution and is able to
image in any plane making it more suited to accurately
quantify RV morphology and function. Furthermore,
contrast imaging allows assessment of focal abnormalities
of the myocardium and an assessment of myocardial
perfusion.113,116
Estimation of pulmonary hemodynamics. In a systematic review
of the literature, the sensitivity and speciﬁcity for echocardiography for diagnosing PH was 83% (95% conﬁdence
interval [CI] ¼ 73–90) and 72% (95% CI ¼ 53–85), respectively. However, echocardiography is less accurate, in lung
disease with sensitivity of 60% and speciﬁcity of 74%.213
Empiric approaches have been used to estimate pulmonary
hemodynamics using MRI.178,180 In a recent study, mPAP
was accurately estimated using multivariate regression analysis of MRI indices, with ventricular mass index and
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interventricular septal angle having additive value in model
for estimation of mPAP.180 It has recently been shown that
with the inclusion of black blood pulmonary arterial slow
ﬂow in addition to ventricular mass index and interventricular septal angle high diagnostic accuracy can be improved
further.147
Right ventricular volumetric and functional assessment. Complete
visualization of the right ventricle with echocardiography
can be challenging, particularly in lung disease, preventing
a complete volumetric evaluation of the right ventricle; this
may be partially negated by the use of 3D echocardiography. MRI has the advantage of complete volumetric
evaluation of the cardiac chambers with good reproducibility of volume, mass, and ejection fraction214 and is considered the gold standard for serial assessment of RV
volume and function.215 Inaccuracies in segmentation of
the right ventricle at the base of the heart and segmentation
of ventricular trabeculations may be improved using threshold-based approaches.
Echocardiography, using pulsed wave and tissue
Doppler, is an established technique for the assessment of
diastolic function. MRI phase contrast evaluation of the
mitral annulus is feasible216 and in a small study imaging
of the mitral valve annulus, in combination with mitral valve
and pulmonary venous ﬂow, was as accurate as echocardiography.217 Other techniques such as myocardial SPAMM
tagging218 and 4D three-directional velocity encoded
MRI219 have been used to evaluate LV diastolic function.
Long analysis times may reduce the applicability for routine
clinical use.
Valvular heart disease. PH may occur in the setting of valvular
heart disease. Echocardiography is the most useful noninvasive technique and has the advantage over MRI in
that it has high temporal resolution and allows accurate
quantiﬁcation of the severity of valvular heart disease.
Left-sided valvular heart disease is a common cause of
group 2 PH. Contemporary studies suggest a prevalence
of PH of 30–40% in patients with mitral stenosis220 upwards
of 30% in patients with severe mitral regurgitation;221 in
asymptomatic patients, the presence of PH serves as an indication for valve surgery.222 With the emergence of transcatheter aortic valve replacement, PH has been noted in
up to 75% of patients with severe aortic stenosis.223
Currently, echocardiography is the recommended non-invasive technique for the assessment of the presence and severity of valvular disease given its advantages over MRI
including availability, low cost, high temporal resolution,
and widespread experience over many years. Despite this,
there are instances in which echo is limited due to poor
acoustic windows, lack of agreement across quantitative
methods, and signiﬁcant inter- and intra-observer variability, which has led to interest in the emerging role of MRI in
the assessment of valvular heart disease.224,225

2.4 Can imaging replace cardiac catheterization in the
assessment of suspected pulmonary hypertension?
Summary statements
1. Cardiac catheterization is the gold standard for the measurement of PAP.
2. CT and MRI may suggest the diagnosis of PH and quantitative MRI metrics can be used to conﬁrm the presence
of PH with high accuracy.
3. At diagnosis MRI and cardiac catheterization provide
equivalent levels of prognostic information.
4. Cardiac catheterization is currently the only way to identify patients with IPAH likely to beneﬁt from calcium
antagonist therapy.
Current ESC/ERS guidelines226 recommend RHC for the
deﬁnitive diagnosis of PH, assessment of intra-cardiac
shunting, and vasodilator testing in selected patients to identify the 10% of patients with IPAH who may beneﬁt from
high-dose calcium antagonist therapy. Measurements such
as right atrial pressure, cardiac index, and mixed venous
oxygen saturation have prognostic value,227–229 and serial
measurements are currently recommended to assess the
response to therapy.226 The procedure requires meticulous
attention to detail but in expert hands is safe in adults with a
morbidity of approximately 1% and mortality of 0.055%,230
although the risk of complications is signiﬁcantly higher in
children. Well established criteria at right heart catheter
exist to assess patients with IPAH likely to beneﬁt from
calcium antagonist therapy. However, no such criteria
exist for imaging metrics.
Although current guidelines discuss the role of CT and
MRI in the classiﬁcation of PH, they are currently considered an adjunct and not yet considered a replacement
for RHC.

2.5 What is the role of imaging in assessing prognosis
and response to treatment?
Summary statements
1. Echocardiography allows assessment of RV function and
measurements such as right atrial area, RV fractional
area change, and tricuspid annular plane systolic excursion have prognostic value.
2. CT imaging provides prognostic information in PAH but
its role in follow-up is currently limited by exposure to
radiation.
3. A number of cardiac MRI metrics have prognostic value
and changes in cardiac MRI parameters at follow-up
reﬂect changes in functional capacity and survival.
4. Adjustment of RV functional measurements for age and
sex improves prognostication.
5. Changes in RV function measured by MRI have prognostic value.
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Echocardiography is widely available and a number of metrics have been shown to have prognostic value including
right atrial area,231 RV fractional area change,
TAPSE,232–234 and the presence of a pericardial eﬀusion.231,235 Echocardiography is widely used, in many centers to assess the response to treatment, acknowledging
issues of operator-dependency and reproducibility.
Several measurements made at CTPA—including RV to
LV ratio, right atrial size, and a posteriorly deviated interventricular septum—predict prognosis in PAH subgroups
while the presence of pleural eﬀusions, septal lines, and
increased inferior vena cava area were independent predictors of a worse outcome in PAH at presentation regardless of subgroup.38 Although this may be helpful at
presentation to guide urgent assessment and introduction
of emergency therapies, the availability of other imaging
modalities and associated radiation exposure necessitates
that CT is not recommended in the assessment of treatment
response.
In contrast, the highly reproducible nature and non-invasive and non-ionizing nature of MRI makes it an ideal
modality to assess treatment response and in the EUROMR study236 changes in MRI measured cardiac index and
RV RVEF correlated with changes in World Health
Organization functional class and survival. A study examining changes in cardiac MRI parameters demonstrated that
this was a better predictor of outcome than PVR measured
invasively at cardiac catheterization.215 MRI metrics including increased RV volumes, reduced LV volumes, stroke
volume, cardiac output, and pulsatility of the vasculature
predict a worse outcome in PAH although there is currently
no large study comparing the prognostic value of cardiac
MRI and right heart catheter measures.

2.6 How can we improve imaging techniques to make
them more acceptable to patients?
Summary statements
1. Minimizing radiation dose by the use of non-ionizing
techniques where possible and implementation of dose
reduction protocols will reduce the risks to patients.
2. Involvement of patients in investigative decision-making
will allow a more tailored approach to investigation.
While plain chest radiographs and echocardiography are
generally well-tolerated and acceptable examinations,
cross-sectional techniques do have some speciﬁc limitations
and issues, in particular radiation doses for CT and claustrophobia for MRI.
The diagnostic information provided by CT needs to be
balanced with the radiation dose. In a life-shortening illness,
concerns regarding radiation exposure rarely impact on the
decision to perform CT imaging at the time of diagnosis.
Advances in dynamic imaging, with improved temporal
resolution, has provided hope that gated CT can challenge
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MRI in the assessment of cardiac function; however, such
examinations typically involve higher doses of radiation.
Using iterative reconstruction, dose reduction can be
achieved.237 In fact, large reductions in dose to less than
one-third the dose of standard acquisitions have been
achieved without loss of image quality using iterative reconstruction,238 and the use of dynamic Z axis collimation has
been shown to further reduce dose.239
Limitations of MRI include long scanning times and
scanner noise, and frequently patients feel claustrophobic
(5%) leading to incomplete examinations. Developments
to reduce scanning time, e.g. novel rapid imaging techniques, and limiting the study to the most clinically relevant
sequences may help. The more widespread installation of
wide bore scanners may help to reduce claustrophobia and
make MRI a more acceptable imaging modality for all
patients. The use of media entertainment may improve
acceptability to patients. More patient involvement in discussions around the implications of the tests are needed.
Patient participation is advised to determine the issues
most relevant to patients to help develop imaging services.

Section 3 Imaging pathway for suspected
pulmonary hypertension in adults
3.1 Current guidelines
The ESC/ERS guideline on diagnostics and therapy of PH
review current imaging modalities and make a number of
recommendations for incorporation in a diagnostic strategy.2 Echocardiography is recommended as a ﬁrst-line
non-invasive diagnostic investigation in case of suspicion
of PH. Chest X-ray and high-resolution CT are recommended in patients with high or intermediate probability
of PH following echocardiography and high-resolution CT
should be considered in all patients with PH. Ventilation/
perfusion or perfusion lung scan is recommended in patients
with unexplained PH to exclude CTEPH. Contrast CT angiography of the PA circulation is recommended and pulmonary (catheter-based) angiography should be considered in
the work-up of patients with CTEPH. There are no recommendations for the use of MRI as part of the diagnostic
strategy or algorithm and no discussion of emerging techniques.240,241 Current American College of Chest Physicians
guidelines on PH provide no speciﬁc recommendations on
employing imaging as part of a diagnostic strategy in
patients with suspected PH.242
The Cologne Consensus Conference 2016 provides no
additional imaging guidelines.

3.2 PVRI diagnostic imaging pathway
Initial assessment and identification of risk factors. In patients
presenting with symptoms and/or signs suggestive of PH,
a detailed history and the results of basic tests are key in
determining the diagnostic strategy (Fig. 1). Risk factors for
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Fig. 1. PVRI diagnostic algorithm. In this algorithm, patients are classified into low, intermediate, and high risk of PH according to ESC/ERS
guidelines.2 See section 3.2 for a detailed description of how to navigate the algorithm. *For patients with rapidly progressive symptoms
and a high probability of PH on echocardiography do not delay referral to PH centre to complete imaging investigations. PH,
pulmonary hypertension; PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; ECG, electrocardiogram; DLco, diffusing capacity of the lungs for carbon monoxide; CXR, chest radiograph; CMRI, cardiac magnetic resonance imaging; CTPA,
computed tomography pulmonary angiography; DECTA, dual-energy computed tomography angiography; CT-LISM, computed tomography lung
iodine subtraction mapping; SPECT, single photon emission computed tomography; RV, right ventricular.

treatable forms of PH (PAH and CTEPH) must be
sought as their presence reduces the threshold for further
imaging. Basic investigations including an electrocardiogram, lung function with gas transfer factor, and a plain
radiography may suggest an alternative diagnosis194 or
increase the probability of PH. Further investigation may
not be required when a conﬁdent alternative diagnosis can
be made.

Sub-optimal echocardiography. For patients with a sub-optimal
echocardiogram, imaging with cardiac MRI can be used to
identify patients at increased risk of PH although currently
used metrics cannot conﬁdently exclude mild PH.147 A
number of metrics on CTPA have been shown to reﬂect
elevated PAPs in addition to providing information on
other potential causes for breathlessness; although evidence
is limited, this may be considered in selected patients.91,95

Echocardiograpy. Echocardiography is the recommended ﬁrstline imaging modality in the assessment of suspected PH
and allows evaluation of cardiac structure and function
and an estimate of PAP. Following echocardiography,
patients should be stratiﬁed into those at low, high, or intermediate probability of PH according to ESC/ERS guidelines.194 Where patients have rapidly progressive symptoms
and a high probability of PH from echocardiography, physicians should not delay referral to expert centers until the
above investigations are completed.

Low
probability
of
pulmonary
hypertension
from
echocardiography. For symptomatic patients identiﬁed as
low probability from echocardiography, further assessment
is dependent on the presence or absence of risk factors. For
those with risk factors for CTEPH, perfusion lung imaging
is recommended using CT imaging (CT-LSIM of DECTA),
nuclear medicine techniques (ideally SPECT), or MRI perfusion imaging.39,81,86,243 If risk factors for PAH exist, the
diagnostic strategy will be dependent on the risk factor; in
systemic sclerosis, given the high prevalence of PAH in
symptomatic patients, further evaluation is advised and a
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number of screening regimens exist such as DETECT.244
For other at-risk patients, an interval echocardiographic
examination may be appropriate.194
High or intermediate probability of pulmonary hypertension from
echocardiography and assessment for left heart disease. For
patients with intermediate or high probability of PH, the
echocardiogram should be evaluated for evidence of left
heart disease such as signiﬁcant valvular heart disease, LV
systolic or diastolic dysfunction. If present, the history
should be re-reviewed to assess for risk factors for left
heart disease (hypertension, obesity, coronary artery disease, diabetes mellitus, atrial ﬁbrillation). Where risk factors
for PAH or CTEPH are absent and risk factors for left heart
disease present, PAP modestly elevated, left atrial size
increased, no paradoxical septal motion, and/or signiﬁcant
RV dysfunction present, then no further investigation to
assess for PH may be required. However, where risk factors
for PAH or CTEPH are present, RV function is severely
impaired, systolic PAP is severely elevated (70 mmHg),
and/or paradoxical septal motion exists, then further investigation to exclude other causes of PH should be considered.26 If no features of left heart disease exist, patients
should undergo CT pulmonary angiography if no contraindications exist.
CT pulmonary angiography. Where left heart disease is
excluded, or if present and other causes of PH cannot be
conﬁdently excluded, then cross-sectional imaging with CT
including CT pulmonary angiography should be considered
as it can aid in: (1) assessment of the likelihood of PH; (2)
classiﬁcation of disease (identifying features of co-existing
lung disease or left heart disease); and (3) identiﬁcation of
patients with CTEPH.38 If features of CTEPH are identiﬁed
at this stage, patients should be referred directly to a center
experienced in the management of PH for further
evaluation.
Perfusion lung imaging. If CTPA is sub-optimal, indeterminate, or is performed by a center not experienced in the
assessment of PH and CTEPH is not identiﬁed, in the
absence of signiﬁcant parenchymal lung disease, perfusion
lung imaging (Q-SPECT of 3D MR perfusion) is advised at
this stage. CT lung subtraction iodine mapping (CT-LISM)
or DECT in addition to directly visualizing abnormalities in
the pulmonary arterial tree also allows construction of perfusion lung maps, preventing the need for other forms of
perfusion lung imaging to exclude CTEPH.81,86,199,245
Supplementary investigations including tests to assess for
conditions associated with PAH such as connective tissue
disease and HIV infection should be considered.1,194
Review and integration of imaging investigations with other tests and
assessment for respiratory disease. Following imaging, the
results should be integrated with the patient’s clinical characteristics. CT imaging may identify unexpected ﬁndings
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such as thromboembolic disease or parenchymal lung disease. Given the current lack of evidence for speciﬁc interventions targeting the pulmonary vasculature for patients
with PH in the context of respiratory disease current therapies should be aimed at the underlying condition, recognizing that the presence of PH identiﬁes patients at increased
risk of death; where appropriate options such as transplantation should be explored. In patients with respiratory disease with risk factors for PAH or CTEPH, signiﬁcant RV
dysfunction or severe elevation in systolic PAP
(70 mmHg), referral to a PH center should be considered;
selected patients may be entered into studies or receive a
trial of therapy. In addition to pulmonary vascular phentoypes increasingly recognized in respiratory disease,4,246,247
these patients may have other forms of PH such as undiagnosed connective tissue disease or CTEPH.247 Where uncertainty exists, discussion or referral to a PH center is
recommended.
Referral or discussion with a pulmonary hypertension referral
center. PH referral centers provide an environment where
specialists are experienced in the assessment of patients
with suspected PH. They also provide speciﬁc therapies
and support for people aﬀected by PH. Imaging investigations will be reviewed and, where sub-optimal, may be
repeated. At this stage, further investigation will usually
be dependent on the pre-test probability of diﬀerent forms
of PH (Table 1). For patients considered for treatment, cardiac catheterization is recommended.
CTEPH suspected. For those with evidence of CTEPH on
CTPA or with risk factors such as previous pulmonary
embolus, deep venous thrombosis, splenectomy, or pacemakers, further evaluation of (1) the pulmonary vasculature
with DSA or MRA, (2) lung perfusion, with SPECT or 3D
MR perfusion, DECTA/CT-LISM, (3) lung ventilation, (4)
biventricular function, with cardiac MRI or 3D echo, and
(5) coronary or further cardiac valvular assessment, if risk
factors for ischemic heart disease exist or co-existant valvular heart disease is noted, and the patient is considered a
candidate for pulmonary endarterectomy, may be performed. The choice of investigations is also dependent on
the preference of PH referral center, where pulmonary endarterectomy or BPA, is being considered. RHC with measurement of PAWP and PVR will aid decisions regarding
appropriateness of the intervention and to conﬁrm the presence of PH. Where ﬁlling defects extend into the proximal
PA and or RV outﬂow tract, other conditions such as sarcoma should be considered and FDG-PET-CT may be
helpful.248,249
Patients with risk factors for specific forms of pulmonary
hypertension. In patients with risk factors for speciﬁc forms
of PAH, further investigation should be tailored; ultrasound
examination of the liver with portal Doppler ultrasound
should be performed in patients suspected of underlying
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Table 1. Recommended imaging investigations in adults with pulmonary hypertension considered for specific pulmonary vascular interventions.
Imaging investigations
All patients

Liver disease suspected or known
Congenital heart disease suspected or known

Left heart disease or respiratory disease
Suspected CTEPH

Unexplained hypoxemia

Follow-up of RV function

Echocardiography
CTPA or DECTA or CT-LSIM
Perfusion lung imaging in selected patients (see section 3.2)
Ultrasound scan of liver with portal Doppler
Consider:
MRI with Qp:Qs
Transesophageal echocardiogram
Cardiac MRI or further echocardiographic studies to assess RV function may reduce
the need to proceed to cardiac catheterization
Consider: MR angiography or digital subtraction angiography
Lung ventilation
If malignant obstruction suspected FDG-PET CT recommended
Consider: Bubble echocardiography
Renal Q SPECT
Cardiac MRI Qp:Qs
MR time-resolved imaging
Echocardiography
Cardiac MRI

CTPA, CT pulmonary angiography; DECTA, dual-energy computed tomography angiography; CT-LSIM, computed tomography lung subtraction iodine mapping;
CMRI, cardiac magnetic resonance imaging; Qp:Qs, pulmonary–systemic flow ratio; FDG-PET CT, fluorodeoxyglucose-positron emission tomography computed
tomography; SPECT, single photon emission computed tomography.

liver disease/portal hypertension. In cases where congenital
heart disease is suspected (features such as anomalous pulmonary venous drainage or atrial septal defect may have
been detected on CT or transthoracic echocardiography),
transesophageal echocardiography and or cardiac MRI to
estimate Qp:Qs ratio and cardiac catheterization with a saturation run should be considered.250,251 In patients with PH,
where the cause is felt to primarily related to left heart disease or respiratory disease, RHC may be required to assess
disease severity particularly if a trial of treatment is contemplated. Further assessment of RV function in these patients
may be helpful, particularly where the echocardiographic
assessment of RV function was challenging; ﬁndings at cardiac MRI of preserved or mildly impaired RV function or a
normal septal angle in PH-LHD (suggesting the absence of a
pre-capillary component) may negate the need for RHC.124
Unexplained pulmonary hypertension. Where no obvious cause
of PH exists, following review of imaging and integration
with other clinical characteristics, cardiac catheterization
with vasodilator testing should be performed to identify
the 10% of patients with IPAH who have a fall in mPAP
or at least 10 mmHg to <40 mmHG with no reduction in
cardiac output, who may respond to treatment with highdose calcium channel blockers.194
Unexplained hypoxemia. Hypoxemia in PH is uncommon at
the time of diagnosis in the absence of respiratory disease,
a right-to-left shunt, or a severely reduced gas transfer
factor. If a right-to-left shunt is suspected, a bubble

echocardiogram, renal perfusion SPECT, or MRI (timeresolved imaging or Qp:Qs) should be considered.
Monitoring of patients at follow-up. Following diagnosis, followup assessments of RV function are recommended to aid
risk stratiﬁcation119,215 in combination with a clinical assessment and a measurement of exercise capacity. Cardiac MRI
or echocardiography can be used to assess RV function.
In selected cases, follow-up cardiac catheterization may be
performed.

Section 4.0: Imaging children with suspected
pulmonary hypertension
Summary statements
1. Echocardiography is recommended as the initial imaging
investigation in children with suspected PH.
2. Performance of cardiac catheterization in children frequently requires general anesthesia and is associated
with a higher risk of complications than in the adult
population.
3. Diagnostic imaging strategies diﬀer in children compared
to adults reﬂecting signiﬁcant diﬀerences in disease
etiology.
4. MRI is of additional value in the initial evaluation and
follow-up of PH in conjunction with other non-invasive
techniques such as echocardiography.
5. Imaging techniques should be modiﬁed where possible to
provide adequate diagnostic information while avoiding
anesthesia.
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4.1 Introduction
Imaging provides valuable information that aids the management of patients with PH, from diagnosis and accurate
phenotyping, through to monitoring disease and assessing
response to therapy. The majority of imaging modalities in
medicine and their implementation in hospital environments
have been developed with the needs of adult patients in
mind. While the underlying philosophy and principles of
imaging in children are the same as in adult PH, there are
some challenges which may be more pertinent to imaging
children. With appropriate modiﬁcation these can be
overcome.
4.2 Differences in the spectrum of disease between adults and
children. While pulmonary vascular disease pathophysiology
is very similar, the context in which it occurs in children is
often very diﬀerent to adult cohorts of PH. Most notably,
children are much more likely to have PH in the context of
congenital or developmental abnormalities, whereas in adult
populations co-morbid diseases of aging may be more
important. Large cohorts of pediatric patients with PH demonstrate that PH related to congenital heart disease and PH
related to developmental lung disorders predominate with
IPAH responsible for approximately 20% of published
cohorts and CTEPH responsible for <1% of cases.252
Furthermore, approximately 30% of children with PH
have more than one potentially causal association.253
Finally, in a large proportion of children with PH, the PH
is associated with other rare conditions. Taken together, this
means that the pre-test probabilities of diﬀerent PH etiologies diﬀer from that in adults. This, in turn, aﬀects the overall diagnostic imaging strategy. A diagnostic algorithm for
children has recently been published following the World
Symposium of Pulmonary Hypertension and reﬂects diﬀerences between adults and children.254
4.3 Scale. The pediatric period covers a period from birth to
adulthood. The body undergoes enormous growth and
development during this period of time and body size can
increase by almost two orders of magnitude. Organ structure, function, maturity, and complexity continue to develop
through childhood and again enormously during puberty,
profoundly aﬀecting physiology.
The most obvious change through childhood is in size.
This produces challenges when aiming to distinguish normal
organ size from abnormal, e.g. ventricular volume. A
number of approaches have been adopted to address this
challenge. The ﬁrst is to establish normative data for children throughout childhood and express these in terms of
centile charts or standard deviation (Z) scores. Normative
values in echocardiography in large populations of healthy
children are increasing with normative echocardiographic
values published in pediatrics with Boston z-scores.255,256
Normative values in CMR in large populations of healthy
children is challenging and normative data are sometimes
lacking. A second approach is to adopt ratio–metric
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relationships, i.e. the parameter in question is simply divided
by a measure of body size, e.g. body surface area (BSA), or
is expressed as a ratio against another cardiovascular parameter in the same patient, e.g. PA to Ao size ratio; however, these approaches have signiﬁcant limitations. A more
appropriate and physiologically sound approach to scaling
may be to adopt allometric scaling relationships. This
approach divides the cardiovascular variable of interest by
the body size variable raised to a scalar exponent in the form
x/yb. There are data across a huge range of scales and species which show empirically that this approach eliminates
the eﬀect of body size on cardiovascular structure and function. This approach to scaling or normalization has not been
widely adopted and therefore the relevant scaling exponents
are not well established or accepted.
The effect of scale on imaging resolution. By deﬁnition, in children spatial scales of structures are smaller (i.e. children are
smaller) and temporal scales are typically shorter (i.e. children have higher respiratory rates and higher heart rates).
This therefore aﬀects imaging quality at any given spatiotemporal resolution. While some adaptations are possible
for example higher frequency ultrasound probes for echocardiography, other imaging modalities suﬀer from fundamental physical and engineering limits to their spatial
temporal resolution. Table 2 suggests some approaches
which may improve spatiotemporal resolution of imaging
modality such that they are suitable for smaller patients.

4.4 Intellectual/emotional maturity
Many imaging modalities require the cooperation of the
patient to achieve optimal imaging results. Children are
often emotionally and intellectually less mature than
adults; thus, securing their cooperation can be more challenging and time-consuming. One approach to this which is
widely used is to sedate or anesthetize children; however,
sedation and anesthesia in children with PH is associated
with a substantial risk of morbidity and mortality and it is
desirable to avoid this wherever possible. Imaging in an
appropriate environment with adequate time and support,
e.g. play therapist involvement and time to familiarize
patients with the environment, can substantially improve
cooperation and imaging quality. Distraction techniques
and allowing parents into the imaging room are extremely
helpful.

4.5 Echocardiography in pediatric pulmonary
hypertension
Echocardiography is used as the initial screening diagnostic
imaging for the diagnosis of pediatric PH and the most
important non-invasive tool that is used for routine assessment.47,48,252,257–259 It is used for continued follow-up and
medication management.260 Developments in echocardiography in the past two decades have led to new insights into
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Table 2. Imaging modalities used in pediatric pulmonary hypertension.
Modality

Adaptation

Problem

Echocardiography

Higher frequency probes provide better spatial and temporal resolution in children; optimized sector width and
focal length improves image quality in children
Multislice

High heart rate, small structures but better echo windows
reduced distance from probe to structure of interest

CT imaging
MRI

Rectangular field of view, partial Fourier encoding, patientfriendly MRI environment, use of novel real-time
sequences/under-sampling with novel reconstruction

Small structures, high heart rates, movement, difficulty in
breath holding, need to avoid sedation anesthesia
Small structures, high heart rates and respiratory rates,
movement and difficulty breath-holding, need to avoid
anesthesia

CT, computed tomography; MRI, magnetic resonance imaging.

the structure and function of the right ventricle and its role
in various diseases including PH.261,262 Conventional imaging includes assessment of anatomy in two dimensions
(2D), hemodynamics via Doppler echocardiography, and
qualitative and quantitative evaluation of RV and LV function.47,48,258,260,263–265 Advanced echocardiography includes
evaluation of right heart size and function, myocardial
mechanics, and estimated RV to PA coupling ratio.266–270
Table 3 shows the advantages and limitations of each of
echocardiographic techniques used in pediatric PH. In
recent years, diﬀerent echocardiography parameters have
been found in small studies to be useful in identifying
high-risk patients who are likely to develop adverse clinical
outcomes.269,271–274 Table 4 demonstrates the echocardiographic views needed to obtain the functional parameters
in pediatric PH.

currently not suitable for frequent serial assessment due to
its clinical availability, longer post-processing time, and also
due to the necessary anesthesia required for younger children and neonates.
In summary, children pose a diﬀerent set of challenges to
adult populations when it comes to imaging. Given the
proven beneﬁts of imaging adults with PH, it is appropriate
that all patients including children are allowed to experience
these beneﬁts. Appropriate adaptations to imaging strategy
and environment can achieve high-quality results in the vast
majority of pediatric patients.

4.6 Cardiac magnetic resonance imaging in pediatric
pulmonary hypertension

Summary statements

Cardiac MRI remains the gold standard imaging modality
for assessment of bi-ventricular function and volumes in
pediatric PH.252 MRI-derived functional and volumetric
indices predict morbidity and mortality in pediatric PH
and may provide additional information with respect to
inter-ventricular interactions.120,275 In addition, phase-contrast MRI remains the state-of-the-art ﬂow imaging technique enabling precise ﬂow volume quantiﬁcation and
consequently provides valuable assessment of Qp/Qs ratios
in children with PH associated with congenital heart disease
and intracardiac shunts. Furthermore, parallel or sequential
phase-contrast MRI and pressure evaluation in the catheterization lab has been proposed as a novel and potentially
more reliable method for the calculation of PVR in comparison to standard Fick principle or thermodilution.276,277
Recent studies suggest that pulsatile pulmonary vascular
stiﬀness indices derived by phase-contrast MRI and ultrasound may have a strong prognostic potential to predict
both hard and soft outcomes in pediatric PH.278–280
Lastly, MRA can aid with diﬀerential diagnosis by ﬁne
characterization of the pulmonary vasculature and exclusion
of thrombi. Unlike echocardiography, cardiac MRI is

Section 5 Future directions
5.1 Applications of computational modelling and artificial
intelligence (AI) in pulmonary hypertension

1. Physiological modeling can be used to characterize the
behavior of the cardiopulmonary system.
2. Computational models assessing PA ﬂow have high diagnostic accuracy in suspected PH.
3. Machine learning approaches may assist image segmentation and improve diagnostic and prognostic
assessments.
4. Further work to assess computational approaches versus
current diagnostic approaches in PH is recommended.
Imaging modalities and markers derived based on images
alone have been shown to have clinical potential. Their
interpretation could be enriched by introducing additional
knowledge from the application of mathematical models,
which can bring insights into the hemodynamic system
behavior in health and disease.
Based on mathematical and physical principles, models
of the pulmonary circulation are currently being evaluated
in the translational/clinical research. Electrical analogue
(Windkessel or 0D-zero-dimensional) models supplied by
patient-speciﬁc 2D phase-contrast MRI data have been proposed281,282 to characterize globally the pulmonary circulation in terms of vascular resistance and compliance in

Abnormal PAAT values with z-score <-2
SD were predictive of PH
<8 cm/s may indicate increased risk of
mortality
Abnormal TDI MPI values indicates right
ventricular dysfunction
>1.4 indicates severity of PH and
increased risk of mortality
>1 may indicate increased risk of adverse
events in pediatric PH
Decreased FAC (<35%) correlates with
decreased systolic function
Decreased RV EF (<45%) indicates
decreased RV function

PAAT (ms)

LV EF may be decreased in severe PH via
RV-LV interaction

LV EF (%)

Full volume datasets to evaluate for RV
volumes and function; accurate measurements of RV function and can be
prognostic in PH
RV free wall longitudinal strain maybe
more sensitive in detecting ventricular
function and is prognostic in PH
Quantification of LV function

Clinically easy to obtain

Easy to obtain clinically

Can easily be measured from TR velocity

Can easily be measured in patients

Bi-plane Simpson’s may not be accurate as
the LV is distorted in severe PH

Presence of defined TR velocity in systole
and diastole
Cannot be used in patients with left to
right shunts
Does not take into account of the entire
right ventricle
Required breath-holding for adequate volumes; can be difficult even in single beat
acquisitions when the pediatric probe is
too big
May not have adequate frame rate when
the heart rate is too high

HR-dependent

324

273

268,326

324

325

272

324

323

256,322

320,321

260,263

260,263

319

317,318
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TR, tricuspid regurgitant; RVSP, right ventricle systolic pressure; SPAP, systolic pulmonary arterial pressure; V, velocity; RA, right atrium; PH, pulmonary hypertension; mRAP, mean right atrial pressure; mPAP,
mean pulmonary arterial pressure; RAP, right atrial pressure; DPAP, diastolic pulmonary arterial pressure; PAAT, pulmonary arterial acceleration time; SD, standard deviation; TDI, tissue Doppler imaging; MPI,
myocardial performance index; FAC, fractional area change; RVEF, right ventricle ejection fraction; LVEF, left ventricular ejection fraction.

RV free wall longitudinal strain decrease
indicates decreased systolic RV function

RV strain (%)

3D RV EF (%)

End-systolic
RV/LV ratio
RV FAC (%)

S/D ratio

RV TDI MPI

Can easily be measured in all patients

Can easily be measured in all patients

Alignment of PR maybe better than TR

HR-dependent

Easy to obtain, impaired RV systolic function when the TAPSE is <2 standard
deviation of age-related value

DPAP ¼ 4 V(end-diastolic pulmonary
regurgitation velocity)2 þ RAP
Longitudinal systolic function

Diastolic
PAP (mmHg)
TAPSE (mm)

RV TDI E’ (cm/s)

Single dimension, does not take into
account of the circumferential or radial
function of the RV. Alignment can be a
problem
Poor correlation with RV function and
survival
HR-dependent

Easy to obtain

RVSP ¼ SPAP ¼ 4(TR max)2 þ mRAP. If TR
velocity is >3 m/s, PH may be suspected
mPAP ¼ 4 V(early peak pulmonary
regurgitation velocity)2 þ RAP

TR peak
velocity (m/s)
mPAP (mmHg)
Alignment of PR maybe better than TR

Qualitative. Can occur in systole and diastole depending on pressure or volume
overload
Poor validation with clinically relevant
measures
75% is measurable
Modest correlation with SPAP
PR required for measurement
Modest correlation with mPAP
Not substitute for cardiac catheterization
PR required for measurement

Quick visual assessments when there is not
adequate TR peak velocity to estimate
RVSP

Mild, moderate, or severe to indicate the
severity of PH

Limitations

Interventricular
septal flattening

Advantage

Interpretation

Echo variables

Table 3. Echocardiographic variables used at diagnosis and follow-up in pediatric PH.
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Table 4. Echocardiographic views to obtain functional parameters in pediatric PH.

Anatomy
Doppler

View

Functional parameters

Parasternal short axis
Parasternal short axis

End-systolic RV/LV ratio325
Pulmonary acceleration time/ejection time
Pulmonary regurgitation early and late diastolic velocity
Tricuspid regurgitation severity (none, mild, moderate, severe)
Tricuspid regurgitation peak velocity
Myocardial performance index (tricuspid tissue Doppler)327
Systolic/diastolic (S/D) duration ratio from TR Doppler272
Tissue Doppler systolic and diastolic velocities (tricuspid, septal, mitral)
Right atrial area (RA)
Qualitative RV function (good, mildly/moderately/severely depressed)
RV end-diastolic and end-systolic dimensions indexed for BSA (2D)
Fractional area of change (FAC) %
Tricuspid annular planar systolic excursion (TAPSE) with z-score
(M-mode when available, 2D)
RV strain (global and segmental)43,326,328
3D RV volumes and function268,326
LV ejection fraction (bi-plane Simpson or 5/6 area-length method)
LV eccentricity index317
LV strain (global)329
3D LV volumes and function324
Presence and severity of pericardial effusion (none, small, moderate, large)231

Apical four-chamber

Right atrium
Right ventricle

Apical four-chamber
Apical four-chamber

Left ventricle

Apical two- and four-chamber

Other

RV, right ventricle; LV, left ventricle; TR, tricuspid regurgitant jet; BSA, body surface area.

healthy and PH patients. They have also shown promising
results for quantifying the changes of the electric parameters
in patients with PAH, at baseline and follow-up.283 Wave
transmission (one-dimensional [1D]) models are particularly
powerful, as ‘‘waves carry information,’’ and the
energy282,284,285 contained in the backward reﬂected wave
can be used as an indicator between the right ventricle and
its afterload mismatch. Using a 1D model of a straight elastic tube and temporal MRI ﬂow and area waveforms, it has
been shown that, on average, >40% of the total wave power
was contained in the backward wave measured in patients
with PH, whereas <20% was characteristic to the healthy
volunteers group.282 Diﬀerent PH heterogeneities can be
mimicked by modifying the structural and elastic parameters of a 1D pulmonary tree structure. Several
authors285–287 investigated the pressure and ﬂow waveforms
in healthy and several simulated PH conditions using
numerical solutions of 1D models of the major vessel network. Notably, Qureshi et al.285 changed the conﬁguration
of the structured tree and altering, in turn, the compliance of
the large and small vessels to predict the hemodynamic
changes induced by PAH, CTEPH, and hypoxic lung disease. The authors showed an increase in the reﬂected waves
under these simulated conditions, with the potential to differentiate between diﬀerent PH phenotypes.
The 0D and 1D models have the main advantage that they
are relatively simple to implement and do not require signiﬁcant computing resources. However, 3D computational ﬂuid
dynamics (CFD) models are more complex, being able to
provide
patient-speciﬁc
characterization
of

hemodynamics.288,289 Full 3D CFD simulations can resolve
the physiological ﬂow ﬁeld in all three directions and time.
Further post-processing of the CFD results can provide computed metrics (e.g. wall shear stress [WSS]), which give additional insights on disease progression. It has been argued290
that pathological ﬂows in the PA alter cell behavior favoring
vasoconstriction. 3D CFD291,292 studies of the pulmonary
circulation showed that shear stress has an impact on
endothelial health and dysfunction, and reduced WSS in
the proximal PAs were shown to be characteristic to PH
patients.
Machine learning of RV contours to derive tissue motion
has shown to be of prognostic value in PAH and of greater
signiﬁcance than standard cardiac volumetric metrics.293
Such approaches are of great potential, minimizing user
input/error and potentially providing a more complete prognostic assessment. The added value versus measurements
adjusted for age, sex, and BSA,118,294 or standard CMR
strain parameters in PAH is an area for further work.
Machine learning approaches may signiﬁcantly improve
the automation and quantiﬁcation of parameters from imaging. For example, deep learning approaches have already
been utilized for automation of arteriovenous segmentation
of the pulmonary circulation.295
The success of the computational models is closely
related to the available data from the imaging modalities.
Regardless of using the data only to supply the models’
boundary conditions, or integrate it within artiﬁcial intelligence algorithms,296,297 the computational models and imaging modalities play together an essential role in the process
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of non-invasive PH diagnostic, prognostic, and understanding of the disease mechanisms.

Section 6 Conclusion and areas of research
priority
In this statement, we have discussed recent advances in imaging techniques in PH and their clinical application. This is
summarized in the PVRI Imaging Task Force diagnostic
algorithm. Rapidly evolving technologies also provide
opportunities to improve our understanding of PH and
assess the impact of much-needed new therapies. This section identiﬁes areas requiring further research in addition to
highlighting a number of ongoing and planned studies.

6.1 Establishment of normative ranges and repeatability
of imaging techniques
Despite the widespread use of imaging techniques in clinical
practice, there are only limited data on the impact of age,
sex, and ethnicity on commonly used metrics. The studies
conducted to develop normative equations to allow for correction have been performed.298–304 However, given the signiﬁcant impact of age, sex, and ethnicity on morphological
characteristics, more research in this area is warranted to
understand variation across populations.
There is increasing interest in using imaging endpoints in
clinical trials to assess treatment response in the clinic setting.
However, there are limited data on the repeatability of cardiac MRI measurements. The RESPIRE study (clinicaltrials.gov), which should report in the third quarter of
2019, will provide information on the sensitivity to change
relative to measurement repeatability of cardiac MRI morphological and functional data. This will aid the design of
studies considering MRI as a primary endpoint. Even in
the absence of such data, studies such as REPAIR (clinicaltrials.gov) are now using imaging to assess the impact of
pharmacological interventions. The results of these studies
are awaited with interest.

6.2 Comparison of imaging modalities and approaches
There are pros and cons of diﬀerent imaging modalities with
respect to diagnostic performance, repeatability, availability, exposure to ionizing radiation, acceptance to patients,
and cost. Often new imaging modalities and/or approaches
are introduced into clinical practice with limited data. The
cost of conducting large comparative studies and the rapid
advances in the underlying technology that may occur
during the conduct of a study may impact negatively on
decisions to conduct such comparative studies. However,
there is a pressing need to perform such technology appraisals. An important area is the diagnosis of CTEPH, where
there have been signiﬁcant advances in the imaging of the
pulmonary vasculature. Additional data are required to critically evaluate these new techniques and challenge current
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guideline approaches. Importantly, a number of studies are
planned, including the prospective, multicenter, comparative phase III diagnostic trial CHANGE-MRI, a
European multicenter study comparing functional MRI
and VQ-SPECT. This study aims to recruit 1000 patients
(clinicaltrials.org). The INSPIRE study is a pilot noninferiority study comparing iodine subtraction mapping
with VQ-SPECT in patients with suspected CTEPH
(clinicaltrials.gov). A prospective study comparing the
cost and utility of follow-up approaches using echocardiography and cardiac MRI in patients with PAH is highly
desirable.
An additional important area of research is the optimization of initial diagnostic testing and follow-up based on
imaging availability, particularly where imaging and invasive testing are limited

6.3 Combining imaging with other modalities (genetics
and MRI-augmented right heart catheterization)
With advances in genetics and imaging, there is an opportunity to better understand genotype–phenotype associations that
have the potential to aid clinical decision-making.
Heterozygous mutations in the gene-encoding bone morphogentic protein receptor type 2 (BMPR2) are the most common
genetic cause of PAH, occurring in 15% of cases,185 and
have been associated with worse RV function on cardiac
MRI.305 Bi-allelic mutations in the eukaryotic translation initiation factor 2 alpha 5 kinase 4 gene (EIF2AK4) are
described in PVOD and PCH,306,307 which are important to
diagnose given their worse prognosis and poorer response to
PAH therapies. In a large international cohort study,185
patients with PVOD were diagnosed based on radiological
criteria; however, a number of patients who were carriers of
EIF2AK4 were not identiﬁed by imaging alone. These
patients were younger and had a lower gas transfer factor
and greater interlobular septal thickening and mediastinal
lymphadenopathy. This suggests that combining imaging
with genetic testing in at-risk patients has the potential to
improve diagnostics and prognostication. Integration of genetics, clinical data, and imaging is an exciting area for further
research.
Diagnosis and accurate prognostication in patients with
pulmonary vascular disease remains challenging.
Hemodynamic data from RHC provides important information with direct pressure measurement. However, it
does not provide a complete morphological or functional
assessment of the right ventricle and pulmonary circulation.
MRI-augmented catheterization involves invasive RHC performed inside the MRI system.276,308,309 It combines simultaneous invasive hemodynamic and MRI morphological
and functional assessment in a single radiation-free procedure, providing detailed physiological insights. Further work
to investigate the potential advantages in terms of clinical
utility, improved understanding of disease, patient acceptability, and cost is recommended.
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6.4 Improving our understanding of pulmonary vascular
disease by assessing the distal vasculature and using
novel imaging approaches
A limitation of current imaging modalities in PH is the
insensitivity to visualize and interrogate the distal pulmonary arterial vasculature, the primary site of disease in
patients with PAH. Assessing pulmonary perfusion directly
using novel MRI or CT methods may provide a signiﬁcant
insight to the underlying small vessel vasculopathy.
Temporal and spatial heterogeneity of the blood ﬂow in
patients at baseline and during PAH therapy is an area for
further research.
Inhaled Xe129 hyperpolarized gas imaging is an emerging
technique. Reports of hyperpolarized gases in CTEPH have
suggested a potential role in follow-up of patients310 and
abnormalities in IPAH have also been reported.311 A patient
inhales Xe129 gas and ventilation images are acquired. Xe129
possesses relatively high solubility in tissues and blood. The
transit of the gas from gas to dissolved phase can be probed
using MRI spectroscopy. This allows the acquisition of
functional parameters characterizing the gas exchange as
well as gas uptake by imaging the dissolved phase. By studying these Xe129 diﬀusion properties, various microstructure
parameters including alveolar-volume ratio, blood–gas barrier thickness, and surface-to-volume ratio can be
determined.

6.7 The impact of imaging on patients and users
Much of the focus of imaging research is based on the knowledge that can obtained by the images themselves. However,
an important area of investigation is the impact of imaging:
on patients and their families, physicians and healthcare
professionals, researchers who interpret the images, and
healthcare systems that fund imaging. The acceptability,
emotional impact, and cost of clinical pathways to diagnose
and serially assess patients requires further research, including the relative tolerability, risks, and beneﬁts of diﬀerent
imaging approaches. A study evaluated the social and
technological epistemology of clinical decision-making as
mediated by imaging.316 This study illustrated that images
can fulﬁl a mediating role by aiding acquisition of knowledge and facilitating communication in addition to illustrating the highly social aspects of interactions with patients and
within multidisciplinary meetings. Involvement of patients
and their families and users of imaging is required if imaging
is going to fulﬁl its potential.
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6.5 Stress imaging of the cardiopulmonary system
Imaging in patients with suspected PH is usually undertaken
at rest but there is increasing interest in evaluating changes
in PAP and RV function on exercise and following other
acute interventions. Exercise echocardiography is well
described312–315 in the assessment of patients with PH, but
currently its use is not widespread. There is increasing interest in using CMR and augmented MRI RHC to assess cardiopulmonary system on exercise to determine the
diﬀerential response of RV morphology and function in
health and disease. Further evaluation of the eﬀect of
acute interventions such as ﬂuid and acute vasodilator challenges would also be of value.

6.6 Artificial intelligence and applications in
pulmonary hypertension
With the rapid development in machine learning technologies, there is huge potential to improve imaging assessments.
Image acquisition, analysis, and interpretation are areas that
may beneﬁt from integration of AI technologies. There are a
number of recent publications in this area.293,296,297 Notable
areas for further research include acceleration of MRI
acquisition, improved segmentation of the cardiac chambers on CT and MRI and the pulmonary vasculature on
CT, and diagnostic and prognostic classiﬁcation and
interpretation.
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